Galectin Therapeutics Inc.
GALT
$5.70
$0.244.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.35% | -3.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.23% | -41.43% | |||
| Operating Income | 9.23% | 41.43% | |||
| Income Before Tax | -8.82% | 21.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.82% | 21.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.82% | 21.91% | |||
| EBIT | 9.23% | 41.43% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -7.20% | 21.38% | |||
| Normalized Basic EPS | -7.56% | 22.16% | |||
| EPS Diluted | -7.20% | 21.38% | |||
| Normalized Diluted EPS | -7.56% | 22.16% | |||
| Average Basic Shares Outstanding | 1.19% | 0.38% | |||
| Average Diluted Shares Outstanding | 1.19% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||